2,605 Shares in IQVIA Holdings Inc. (NYSE:IQV) Bought by Abound Financial LLC

Abound Financial LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 2,605 shares of the medical research company’s stock, valued at approximately $512,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Private Trust Co. NA grew its position in IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after acquiring an additional 47 shares in the last quarter. Clear Harbor Asset Management LLC boosted its position in IQVIA by 1.3% during the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after buying an additional 50 shares during the period. Pine Valley Investments Ltd Liability Co boosted its position in IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after buying an additional 50 shares during the period. Fortitude Family Office LLC boosted its position in IQVIA by 2.9% during the third quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock valued at $468,000 after buying an additional 56 shares during the period. Finally, Huntington National Bank boosted its position in IQVIA by 7.4% during the third quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock valued at $192,000 after buying an additional 56 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at IQVIA

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $190.94 on Friday. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a market cap of $33.62 billion, a P/E ratio of 25.46, a PEG ratio of 1.99 and a beta of 1.48. The firm has a 50-day moving average of $199.57 and a 200 day moving average of $216.34. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Barclays cut their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, Bank of America lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $251.22.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.